We would expect that LAAs such as RHAMM, PRAME, and WT1 (reviewed in (Sugiyama, 1998) would provide better markers of MRD due to their frequent expression in AML patients samples as compared to cancer-testis (CT) antigens such as HAGE (Adams et al. 2002), BAGE (Greiner et al. 2004), RAGE-1 (Guinn et al. 2005b), PASD1 (Guinn et al. 2005a) and MAGE-A3 (Martinez et al. 2007) whose expression was, at most, found in 33% of AML patients at presentation. Here, DDX43 is linked to acute myeloid leukemia.